Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus TPF induction therapy for locally advanced nasopharyngeal carcinoma
ChiCTR2400086030Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jun 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, docetaxel, cisplatin and fluorouracil in nasopharyngeal carcinoma (NPC), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Complete response rate after induction therapy. Started Jun 2024; status: recruiting.
02
Drugs
camrelizumabdocetaxelcisplatinfluorouracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2400086030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086030.